Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Dividends payables: 2011-2014

Historic Dividends payables for Abeona Therapeutics (ABEO) over the last 4 years, with Sep 2014 value amounting to $9.3 million.

  • Abeona Therapeutics' Dividends payables rose 58.04% to $9.3 million in Q3 2014 from the same period last year, while for Sep 2014 it was $9.3 million, marking a year-over-year increase of 58.04%. This contributed to the annual value of $6.7 million for FY2013, which is 91.14% up from last year.
  • According to the latest figures from Q3 2014, Abeona Therapeutics' Dividends payables is $9.3 million, which was up 10.80% from $8.4 million recorded in Q2 2014.
  • Over the past 5 years, Abeona Therapeutics' Dividends payables peaked at $9.3 million during Q3 2014, and registered a low of $2.8 million during Q3 2012.
  • Its 3-year average for Dividends payables is $6.2 million, with a median of $6.7 million in 2013.
  • Its Dividends payables has fluctuated over the past 5 years, first plummeted by 53.65% in 2012, then soared by 112.30% in 2013.
  • Quarterly analysis of 4 years shows Abeona Therapeutics' Dividends payables stood at $6.5 million in 2011, then tumbled by 46.26% to $3.5 million in 2012, then soared by 91.14% to $6.7 million in 2013, then skyrocketed by 58.04% to $9.3 million in 2014.
  • Its Dividends payables was $9.3 million in Q3 2014, compared to $8.4 million in Q2 2014 and $7.5 million in Q1 2014.